Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Receivables (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Receivables for 5 consecutive years, with $15.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables fell 62.63% year-over-year to $15.6 million, compared with a TTM value of $15.6 million through Dec 2025, down 62.63%, and an annual FY2025 reading of $15.6 million, down 62.63% over the prior year.
  • Receivables was $15.6 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $51.7 million in the prior quarter.
  • Across five years, Receivables topped out at $51.7 million in Q3 2025 and bottomed at $2.6 million in Q2 2021.
  • Average Receivables over 5 years is $19.9 million, with a median of $20.3 million recorded in 2022.
  • The sharpest move saw Receivables crashed 74.78% in 2023, then surged 718.41% in 2024.
  • Year by year, Receivables stood at $4.0 million in 2021, then surged by 409.81% to $20.3 million in 2022, then grew by 4.68% to $21.3 million in 2023, then surged by 96.2% to $41.7 million in 2024, then tumbled by 62.63% to $15.6 million in 2025.
  • Business Quant data shows Receivables for KNSA at $15.6 million in Q4 2025, $51.7 million in Q3 2025, and $31.9 million in Q2 2025.